WallStreetZenWallStreetZen

NASDAQ: EYPT
Eyepoint Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for EYPT

Based on 5 analysts offering 12 month price targets for Eyepoint Pharmaceuticals Inc.
Min Forecast
$28.00+136.49%
Avg Forecast
$33.40+182.09%
Max Forecast
$44.00+271.62%

Should I buy or sell EYPT stock?

Based on 5 analysts offering ratings for Eyepoint Pharmaceuticals Inc.
Strong Buy
Strong Buy
3 analysts 60%
Buy
2 analysts 40%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their EYPT stock forecasts and price targets.

EYPT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-13
lockedlocked$00.00+00.00%2024-05-08
lockedlocked$00.00+00.00%2024-05-07
lockedlocked$00.00+00.00%2024-05-07
lockedlocked$00.00+00.00%2024-01-22
Capital One Financial
Top 4%
97
BuyInitiates Coverage On$44.00+271.62%2023-12-11

1 of 1

Forecast return on equity

Is EYPT forecast to generate an efficient return?

Forecast return on assets

Is EYPT forecast to generate an efficient return on assets?

EYPT revenue forecast

What is EYPT's revenue in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
$45.3M-9.52%
Avg 2 year Forecast
$14.3M-71.36%
Avg 3 year Forecast
$6.5M-87%

EYPT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
EYPT$11.84$33.40+182.09%Strong Buy
VALN$8.88$21.50+142.12%Strong Buy
PHAT$10.54$26.00+146.68%Strong Buy
ORIC$9.16$19.17+109.25%Strong Buy
SVRA$4.48$10.00+123.21%Strong Buy

Eyepoint Pharmaceuticals Stock Forecast FAQ

Is Eyepoint Pharmaceuticals Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: EYPT) stock is to Strong Buy EYPT stock.

Out of 5 analysts, 3 (60%) are recommending EYPT as a Strong Buy, 2 (40%) are recommending EYPT as a Buy, 0 (0%) are recommending EYPT as a Hold, 0 (0%) are recommending EYPT as a Sell, and 0 (0%) are recommending EYPT as a Strong Sell.

If you're new to stock investing, here's how to buy Eyepoint Pharmaceuticals stock.

What is EYPT's revenue growth forecast for 2024-2026?

(NASDAQ: EYPT) Eyepoint Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.19%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.

Eyepoint Pharmaceuticals's revenue in 2024 is $50,019,000.On average, 4 Wall Street analysts forecast EYPT's revenue for 2024 to be $2,357,182,559, with the lowest EYPT revenue forecast at $1,689,096,281, and the highest EYPT revenue forecast at $2,864,640,625. On average, 4 Wall Street analysts forecast EYPT's revenue for 2025 to be $746,108,672, with the lowest EYPT revenue forecast at $156,253,125, and the highest EYPT revenue forecast at $1,239,608,125.

In 2026, EYPT is forecast to generate $338,548,438 in revenue, with the lowest revenue forecast at $156,253,125 and the highest revenue forecast at $520,843,750.

What is EYPT's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: EYPT) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is EYPT's Price Target?

According to 5 Wall Street analysts that have issued a 1 year EYPT price target, the average EYPT price target is $33.40, with the highest EYPT stock price forecast at $44.00 and the lowest EYPT stock price forecast at $28.00.

On average, Wall Street analysts predict that Eyepoint Pharmaceuticals's share price could reach $33.40 by May 13, 2025. The average Eyepoint Pharmaceuticals stock price prediction forecasts a potential upside of 182.09% from the current EYPT share price of $11.84.

What is EYPT's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: EYPT) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.